2017
Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery
Salazar MC, Rosen JE, Wang Z, Arnold BN, Thomas DC, Herbst RS, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ. Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery. JAMA Oncology 2017, 3: 610-619. PMID: 28056112, PMCID: PMC5824207, DOI: 10.1001/jamaoncol.2016.5829.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantDrug Administration ScheduleFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasm GradingNeoplasm StagingPneumonectomyPostoperative PeriodProportional Hazards ModelsRetrospective StudiesTreatment OutcomeUnited StatesConceptsLung cancer surgeryCell lung cancer resectionAdjuvant chemotherapyLung cancer resectionNational Cancer DatabaseCell lung cancerLower mortality riskCancer surgeryCox modelCancer resectionLung cancerCancer DatabaseMortality riskCell lung cancer surgeryHospital-based tumor registryIncident lung cancer casesPostoperative multiagent chemotherapyInitiation of chemotherapyTreatment-naive patientsPropensity-matched pairsRetrospective observational studyLymph node metastasisLung cancer casesChemotherapy initiationPostoperative chemotherapy
2009
Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer
Rivera MP, Detterbeck FC, Socinski MA, Moore DT, Edelman MJ, Jahan TM, Ansari RH, Luketich JD, Peng G, Monberg M, Obasaju CK, Gralla RJ. Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer. CHEST Journal 2009, 135: 1588-1595. PMID: 19188545, DOI: 10.1378/chest.08-1430.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCisplatinConfidence IntervalsDeoxycytidineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesGemcitabineHumansLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelPneumonectomyPreoperative CareProbabilityRespiratory Function TestsRisk AssessmentSurvival AnalysisConceptsNon-small cell lung cancerCell lung cancerSurgical resectionLung cancerPulmonary toxicityResectable early stage non-small cell lung cancerEarly-stage non-small cell lung cancerRandomized phase 2 trialPulmonary function test resultsSecondary end pointsCombination of gemcitabinePhase 2 trialPulmonary function testsGemcitabine-based chemotherapyFunction test resultsTotal lung capacityEligible patientsNonplatinum regimensDyspnea scoreInterstitial pneumonitisPreoperative chemotherapyFunction testsSmoking statusClinical symptomsPreoperative setting
2008
Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer
Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Zaman MB, Ye Z, Monberg MJ, Obasaju CK. Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2008, 3: 37-45. PMID: 18166839, DOI: 10.1097/jto.0b013e31815e5d9a.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCisplatinDeoxycytidineDrug Administration ScheduleFeasibility StudiesFemaleFollow-Up StudiesGemcitabineHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelSurvival AnalysisTime FactorsTreatment OutcomeConceptsEarly-stage non-small cell lung cancerNon-small cell lung cancerCell lung cancerGemcitabine 1000Day 1Neoadjuvant chemotherapyLung cancerResponse ratePathologic complete response rateRandomized phase II trialPhase III settingClinical response rateComplete response ratePerioperative mortality ratePrimary end pointComplete resection ratePhase II trialCarboplatin areaEligible patientsII trialPreoperative regimenResection rateSame regimenUnderwent surgeryMedian survival